These days there are so many novel newly synthesized compounds on the market that it's hard to keep up.
Ones that come to mind are semax (not semanex), FK962 and N-PEP-12.
From the above the only one that is currently commercially avaliable is N-PEP-12. Sold under the brand name "MemoProve".
Here are some abstracts:
Alvarez XA, Corzo L, Laredo M, Sampedro C, Cacabelos R, Windisch M, Moessler H, Crook TH.
Department of Neuropharmacology, EuroEspes Biomedical Research Center, Santa Marta de Babio, Bergonodo, A Coruna, Spain. firstname.lastname@example.org
N-PEP-12 is a dietary supplement consisting of neuropeptides and amino acids. In animal experiments, the compound has been shown to enhance cognitive function and reduce neurodegenerative events associated with aging. In this study, we investigated the effects of a single oral dose of N-PEP-12 (180 mg) on brain bioelectrical activity and cognitive performance in healthy elderly subjects. N-PEP-12 induced a significant (p < 0.05) increase in relative alpha-activity power 6 h after administration. This enhancement was accompanied by a generalized decrease in slow Delta-activity. Significant improvement in memory performance subtests was also seen 6 h after N-PEP-12 administration in some but not in all tests. Taken together, these data suggest that N-PEP-12 might be a reliable dietary supplement to be investigated for improving and, perhaps, maintaining brain function among healthy older adults. © 2005 Prous Science. All rights reserved.
* Clinical Trial
PMID: 16258593 [PubMed - indexed for MEDLINE]
Windisch M, Hutter-Paier B, Grygar E, Doppler E, Moessler H.
JSW-Research Forschungslabor GmbH, Graz, Austria.
The neuroprotective potency of N-PEP-12, a novel, proprietary compound consisting of biopeptides and amino acids was investigated. Lesion models have been applied in neuronal cultures of embryonic chicken cortex, pre-treated with N-PEP-12 from the first day onwards. On day 8 in vitro neurons were lesioned and cell viability was measured 24 and 48 hours later. To simulate acute brain ischemia, cytotoxic hypoxia was induced by sodium cyanide or by iodoacetate and excitotoxicity by L-glutamate. Ionomycin for up to 48 hours induced calcium overload. The cytoskeleton was disrupted by addition of colchicine. N-PEP-12 shows dose-dependent neuroprotection in all different models. The effect size depends on the recovery time but also on the extent of the lesion. In cases of mild to moderate lesion pronounced dose-dependent effects could be demonstrated. This indicates that chronic exposure to N-PEP-12 is able to prevent neuronal cell death associated to conditions occurring during normal aging and neurological disorders like ischemic stroke, hypoxia, brain trauma, or AD.
PMID: 15750682 [PubMed - in process]
Crook TH, Ferris SH, Alvarez XA, Laredo M, Moessler H.
Psychologix, Inc., Fort Lauderdale, FL 33308, USA. email@example.com
N-PEP-12 is a derivative of cerebrolysin, a brain-derived neuropeptide compound that has been approved for the treatment of Alzheimer's disease (AD) in more than 30 countries. N-PEP-12 is much less potent than cerebrolysin but it can be administered orally whereas the parent compound must be administered through multiple intravenous infusions. This study was undertaken to determine whether N-PEP-12 is effective in improving memory and other cognitive abilities among healthy older adults who have experienced 'normal' age-related memory loss. Subjects were 54 males and females, aged 50 years and older, who presented both subjective and objective evidence of memory loss since early adulthood. The study was a fully randomized, double-blind comparison of N-PEP-12 and placebo. Cognitive assessments were performed at baseline and following 30 days of treatment. The primary outcome measure was the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) Memory score, with the Syndrom Kurz Test (SKT) test, digit cancellation, digit span, verbal fluency and clinical ratings as secondary outcomes. N-PEP-12 treated subjects performed better than placebo-treated subjects on the ADAS-cog Memory score, the SKT, clinical ratings and some, but not other tests. N-PEP-12 may be an effective treatment for memory loss in healthy older adults.
* Clinical Trial
* Randomized Controlled Trial
PMID: 15729085 [PubMed - indexed for MEDLINE]
Of the above papers, I have a copy of the 2nd one mentioned. (PM me for details)
Edited by zoolander, 30 March 2006 - 01:37 AM.